Literature DB >> 15790644

Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies.

Silja Rott1, Ulrich Mrowietz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15790644      PMCID： PMC555638          DOI： 10.1136/bmj.330.7493.716

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  26 in total

1.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

Authors:  Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

2.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

Authors:  S Lori Brown; Mark H Greene; Sharon K Gershon; Evelyne T Edwards; M Miles Braun
Journal:  Arthritis Rheum       Date:  2002-12

Review 3.  Side effects of anti-TNF therapy: current knowledge.

Authors:  C Antoni; J Braun
Journal:  Clin Exp Rheumatol       Date:  2002 Nov-Dec       Impact factor: 4.473

4.  Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

Authors:  Leen De Rycke; Elli Kruithof; Nancy Van Damme; Ilse E A Hoffman; Nancy Van den Bossche; Filip Van den Bosch; Eric M Veys; Filip De Keyser
Journal:  Arthritis Rheum       Date:  2003-04

5.  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.

Authors:  Gerald G Krueger; Kim A Papp; Dow B Stough; Keith H Loven; Wayne P Gulliver; Charles N Ellis
Journal:  J Am Acad Dermatol       Date:  2002-12       Impact factor: 11.527

6.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

Review 7.  Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies.

Authors:  Stephen B Hanauer
Journal:  Rev Gastroenterol Disord       Date:  2004

8.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.

Authors:  P J Charles; R J Smeenk; J De Jong; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  2000-11

Review 9.  What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.

Authors:  Michael H Weisman
Journal:  J Rheumatol Suppl       Date:  2002-09

10.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Authors:  Michael E Weinblatt; Edward C Keystone; Daniel E Furst; Larry W Moreland; Michael H Weisman; Charles A Birbara; Leah A Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2003-01
View more
  3 in total

Review 1.  [Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis].

Authors:  G Wozel
Journal:  Hautarzt       Date:  2005-09       Impact factor: 0.751

2.  SD0006: a potent, selective and orally available inhibitor of p38 kinase.

Authors:  Barry L Burnette; Shaun Selness; Raj Devraj; Gail Jungbluth; Ravi Kurumbail; Loreen Stillwell; Gary Anderson; Stephen Mnich; Jeffrey Hirsch; Robert Compton; Pamela De Ciechi; Heidi Hope; Michael Hepperle; Robert H Keith; Win Naing; Huey Shieh; Joseph Portanova; Yan Zhang; Jian Zhang; Richard M Leimgruber; Joseph Monahan
Journal:  Pharmacology       Date:  2009-07-04       Impact factor: 2.547

3.  A synthetic peptide derived from A1 module in CRD4 of human TNF receptor-1 inhibits binding and proinflammatory effect of human TNF-alpha.

Authors:  Yingnan Cao; Zhaohe Wang; Xianzhang Bu; Shu Tang; Zhengrong Mei; Peiqing Liu
Journal:  Inflammation       Date:  2009-06       Impact factor: 4.092
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.